PMID- 36525222
OWN - NLM
STAT- MEDLINE
DCOM- 20230331
LR  - 20230403
IS  - 1559-0100 (Electronic)
IS  - 1355-008X (Print)
IS  - 1355-008X (Linking)
VI  - 80
IP  - 1
DP  - 2023 Apr
TI  - Trends in incidence and mortality risk for acromegaly in Norway: a cohort study.
PG  - 152-159
LID - 10.1007/s12020-022-03275-6 [doi]
AB  - PURPOSE: Recent data have shown a decreasing overall mortality in acromegaly over 
      the last decades. However, cancer incidence and cancer-related mortality still 
      appear to be increased. Our aim was to obtain updated epidemiological data from 
      Norway in a clinically well-defined cohort with complete register-based 
      follow-up. METHODS: Patients diagnosed with acromegaly from South-Eastern Norway 
      between 1999-2019 (n = 262) and age and sex matched population controls (1:100) 
      were included (n = 26,200). Mortality and cancer data were obtained from the 
      Norwegian Cause of Death and Cancer Registry. Mortality and cancer incidence were 
      compared by Kaplan-Meier analyses and Cox regression; we report hazard ratios 
      (HRs) with 95% confidence intervals (95% CI). RESULTS: Median age at diagnosis 
      was 48.0 years (interquartile range (IQR): 37.6-58.0). Mean annual acromegaly 
      incidence rate was 4.7 (95% CI 4.2-5.3) cases/10(6) person-years, and the point 
      prevalence (2019) was 83 (95% CI 72.6-93.5) cases/10(6) persons. Overall 
      mortality was not increased in acromegaly, HR 0.8 (95% CI 0.5-1.4), 
      cancer-specific and cardiovascular-specific mortality was also not increased (HR: 
      0.7 (95% CI 0.3-1.8) and 0.8 (95% CI: 0.3-2.5) respectively). The HR for all 
      cancers was 1.45 (1.0-2.1; p = 0.052). CONCLUSION: In this large cohort study, 
      covering the period 1999-2019, patients were treated with individualized 
      multimodal management. Mortality was not increased compared to the general 
      population and comparable with recent registry studies from the Nordic countries 
      and Europe. Overall cancer risk was slightly, but not significantly increased in 
      the patients.
CI  - (c) 2022. The Author(s).
FAU - Falch, Camilla M
AU  - Falch CM
AUID- ORCID: 0000-0001-9894-5245
AD  - Section of Specialized Endocrinology, Department of Endocrinology, Oslo 
      University Hospital, Oslo, Norway. c.m.falch@studmed.uio.no.
AD  - Faculty of Medicine, University of Oslo, Oslo, Norway. c.m.falch@studmed.uio.no.
FAU - Olarescu, Nicoleta C
AU  - Olarescu NC
AD  - Section of Specialized Endocrinology, Department of Endocrinology, Oslo 
      University Hospital, Oslo, Norway.
AD  - Faculty of Medicine, University of Oslo, Oslo, Norway.
FAU - Bollerslev, Jens
AU  - Bollerslev J
AD  - Section of Specialized Endocrinology, Department of Endocrinology, Oslo 
      University Hospital, Oslo, Norway.
AD  - Faculty of Medicine, University of Oslo, Oslo, Norway.
FAU - Dekkers, Olaf M
AU  - Dekkers OM
AD  - Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, 
      The Netherlands.
AD  - Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Heck, Ansgar
AU  - Heck A
AD  - Section of Specialized Endocrinology, Department of Endocrinology, Oslo 
      University Hospital, Oslo, Norway.
AD  - Faculty of Medicine, University of Oslo, Oslo, Norway.
LA  - eng
PT  - Journal Article
DEP - 20221216
PL  - United States
TA  - Endocrine
JT  - Endocrine
JID - 9434444
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - Cohort Studies
MH  - Incidence
MH  - *Acromegaly/epidemiology
MH  - *Neoplasms/epidemiology
MH  - Norway/epidemiology
MH  - Registries
PMC - PMC10060282
OTO - NOTNLM
OT  - Acromegaly
OT  - Cancer
OT  - Epidemiology
OT  - Incidence
OT  - Mortality
OT  - Prevalence
COIS- A.H. has received speaker fees from Recordati and Ipsen. J.B. has received 
      speaker fees from Ipsen and Pfizer, and has served as an advisory board member 
      for Pfizer. N.C.O. received speaker fees from CORE2ED (supported by a medical 
      education grant from Ipsen). O.M.D. and C.M.F. have nothing to declare.
EDAT- 2022/12/17 06:00
MHDA- 2023/03/31 06:41
PMCR- 2022/12/16
CRDT- 2022/12/16 11:30
PHST- 2022/10/31 00:00 [received]
PHST- 2022/11/27 00:00 [accepted]
PHST- 2023/03/31 06:41 [medline]
PHST- 2022/12/17 06:00 [pubmed]
PHST- 2022/12/16 11:30 [entrez]
PHST- 2022/12/16 00:00 [pmc-release]
AID - 10.1007/s12020-022-03275-6 [pii]
AID - 3275 [pii]
AID - 10.1007/s12020-022-03275-6 [doi]
PST - ppublish
SO  - Endocrine. 2023 Apr;80(1):152-159. doi: 10.1007/s12020-022-03275-6. Epub 2022 Dec 
      16.